Starling Oncology, Inc. Current Income Tax Expense (Benefit)
Starling Oncology, Inc. (STLN) reported Current Income Tax Expense (Benefit) of -$99.00 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-12.
Financial Statements › Expense Statement › Income Tax
us-gaap:CurrentIncomeTaxExpenseBenefit · last filed 2026-03-12
- Starling Oncology, Inc. current income tax expense (benefit) for fiscal 2025 was -$99.00K.
- Starling Oncology, Inc. current income tax expense (benefit) for fiscal 2024 was $0.00, a 100.00% decline from fiscal 2023.
- Starling Oncology, Inc. current income tax expense (benefit) for fiscal 2023 was $40.00K, a 100.00% increase from fiscal 2022.
- Starling Oncology, Inc. current income tax expense (benefit) for fiscal 2022 was $20.00K, a 96.50% decline from fiscal 2021.
| Period end | Current Income Tax Expense (Benefit) 12 month | Current Income Tax Expense (Benefit) 12 month as first filed |
|---|---|---|
| 2025-12-31 | -$99.00K 10-K · filed 2026-03-12 | |
| 2024-12-31 | $0.00 10-K · filed 2026-03-12 | |
| 2023-12-31 | $40.00K 10-K · filed 2025-03-26 | |
| 2022-12-31 | $20.00K 10-K · filed 2024-03-28 | |
| 2021-12-31 | $571.00K 10-K · filed 2023-03-16 | $570.00K 10-K · filed 2022-03-11 |
| 2020-12-31 | $851.00K 10-K · filed 2022-03-11 |